C A. Saura

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 24, 2026

Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study.

Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study.

Journal: ESMO real world data and digital oncology
Published: February 06, 2026

Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial.

Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 22, 2026

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Journal: ESMO open
Published: January 16, 2026

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

Journal: ESMO open
Published: January 05, 2026

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Journal: ESMO open
Published: December 17, 2025

Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project.

Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project.

Journal: ESMO open
Published: November 25, 2025

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 07, 2025

Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors.

Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors.

Journal: ESMO open
Published: September 01, 2025

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.

Journal: ESMO open
Published: June 16, 2025

Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers.

Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers.

Journal: ESMO open
Published: March 26, 2025

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 12, 2025
Showing 1-12 of 32

Last Updated: 09/26/2026